Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
Newly Released DOJ Epstein Files Expose High-Profile Connections Across Politics and Business 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Federal Judge Restores Funding for Gateway Rail Tunnel Project 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
U.S. Lawmakers to Review Unredacted Jeffrey Epstein DOJ Files Starting Monday 
Trump Administration Appeals Court Order to Release Hudson Tunnel Project Funding 
Democrats Pledge Major Spending on Virginia Redistricting Ahead of Midterm Elections 
Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Sanofi, accusing the company of unlawfully incentivizing healthcare providers to prescribe its medications instead of competing alternatives. According to the attorney general’s office, Sanofi allegedly created service-based programs for healthcare professionals that effectively functioned as bribes, in violation of the Texas Health Care Program Fraud Prevention Act.
State officials claim these programs were designed to improperly influence prescribing decisions, potentially impacting fair competition and patient care within Texas healthcare programs. The lawsuit seeks more than $1 million in monetary relief, including civil penalties, as well as a court injunction to prevent any further alleged unlawful conduct.
Sanofi has strongly denied the allegations. In a public statement, the company asserted that its services are fully structured to comply with both federal and state regulations. Sanofi emphasized that the programs are intended to support patient care and improve health outcomes, not to sway physicians’ prescribing behavior. The company also stated that the state’s legal action does not reflect the merits of the case and confirmed it will vigorously defend itself in court.
This is not the first time Attorney General Paxton has taken legal action against major pharmaceutical companies. Previously, Texas sued Sanofi and Bristol-Myers Squibb, alleging they failed to disclose that their blood thinner Plavix was less effective for certain patients. In a separate case last year, the state filed a lawsuit against Eli Lilly, accusing the drugmaker of bribing healthcare providers to prescribe its top-selling medications, including GLP-1 drugs Mounjaro and Zepbound.
The latest lawsuit highlights Texas’ continued scrutiny of pharmaceutical industry practices, particularly regarding alleged healthcare fraud, drug marketing tactics, and compliance with state healthcare laws.
